Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.

A 16-year-old experiencing diffuse hair thinning is considering using minoxidil and plans to start finasteride at 18, while others suggest alternatives like saw palmetto and pumpkin seed oil. Users advise consulting a doctor before starting treatments and emphasize the importance of understanding the cause of hair loss.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

A user shared their 16-month hair regrowth progress using oral and topical minoxidil, dutasteride, derma rolling, and occasional keto shampoo. The conversation includes positive reactions and jokes about their impressive results.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The user shared 16 months of hair loss treatment progress using finasteride, oral and topical minoxidil, dutasteride, ketoconazole shampoo, and multivitamins. They are not currently planning a hair transplant but are considering it in the future.

A 16-year-old is asking if their hair situation has improved after using rosemary oil, rosemary water, derma rolling, and ketoconazole, and is considering starting Minoxidil. Replies comment on the user's hairiness and high DHT levels.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

The user is experiencing hair thinning and bald spots, using Nizoral, rosemary oil, fluocinolone, and receiving PRP treatments. They are considering oral minoxidil and finasteride but are hesitant due to age and financial constraints.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A 16-year-old has been using Minoxidil for a year, which initially worked but is now less effective as hair loss continues. They are concerned about ongoing hair loss and are unable to use finasteride.

A 16-year-old is experiencing hair loss and feels self-conscious. They are using rosemary oil daily but have not started minoxidil or finasteride.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

A 16-year-old is experiencing hair thinning and has been using 5% minoxidil for three months and finasteride for one month. They are considering adding dutasteride but are concerned about potential side effects like prostate cancer.

Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.

A 16-year-old is experiencing thinning hair at the front and shedding during showers. He is concerned about potential early baldness and is considering seeing a doctor and taking multivitamins.

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

A 25-year-old who started losing hair at 16 and reached almost NW7 by 20 saw hair regrowth using a regimen including dutasteride, minoxidil, nizoral, and a dermaroller, along with supplements like biotin, zinc, and omega-3. After initial success, they experienced shedding, added more supplements and treatments, and sought advice on whether to continue; responses encouraged them to persist as shedding is often part of the hair regrowth cycle.

The user experienced significant hair regrowth using Propecia (finasteride) 1 mg and topical minoxidil twice a day over 16 months, despite initial shedding. The user no longer needs a hair transplant and reports no side effects from the treatment.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.